These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 18823621)
1. Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson's disease. Bharathi P; Nagabhushan P; Rao KS Comput Biol Med; 2008 Oct; 38(10):1084-93. PubMed ID: 18823621 [TBL] [Abstract][Full Text] [Related]
2. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Bharathi ; Indi SS; Rao KS Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865 [TBL] [Abstract][Full Text] [Related]
3. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease. Bharathi ; Rao KS Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952 [TBL] [Abstract][Full Text] [Related]
4. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis. Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751 [TBL] [Abstract][Full Text] [Related]
5. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. Koo HJ; Choi MY; Im H Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571 [TBL] [Abstract][Full Text] [Related]
6. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay. Kramer ML; Behrens C; Schulz-Schaeffer WJ Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794 [TBL] [Abstract][Full Text] [Related]
7. The aggregation and fibrillation of alpha-synuclein. Fink AL Acc Chem Res; 2006 Sep; 39(9):628-34. PubMed ID: 16981679 [TBL] [Abstract][Full Text] [Related]
8. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166 [TBL] [Abstract][Full Text] [Related]
9. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein. Thirunavukkuarasu S; Jares-Erijman EA; Jovin TM J Mol Biol; 2008 May; 378(5):1064-73. PubMed ID: 18433772 [TBL] [Abstract][Full Text] [Related]
10. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459 [TBL] [Abstract][Full Text] [Related]
12. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. Sass MB; Lorenz AN; Green RL; Coleman RA J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028 [TBL] [Abstract][Full Text] [Related]
13. Molecular understanding of copper and iron interaction with alpha-synuclein by fluorescence analysis. Bharathi ; Rao KS J Mol Neurosci; 2008 Jul; 35(3):273-81. PubMed ID: 18491043 [TBL] [Abstract][Full Text] [Related]
14. Controlling the mass action of alpha-synuclein in Parkinson's disease. Kim C; Lee SJ J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382 [TBL] [Abstract][Full Text] [Related]
15. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Kao SY Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380 [TBL] [Abstract][Full Text] [Related]
16. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. Binolfi A; Lamberto GR; Duran R; Quintanar L; Bertoncini CW; Souza JM; Cerveñansky C; Zweckstetter M; Griesinger C; Fernández CO J Am Chem Soc; 2008 Sep; 130(35):11801-12. PubMed ID: 18693689 [TBL] [Abstract][Full Text] [Related]
17. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Angot E; Brundin P Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S143-7. PubMed ID: 20082977 [TBL] [Abstract][Full Text] [Related]
18. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells. Fan GH; Zhou HY; Yang H; Chen SD FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164 [TBL] [Abstract][Full Text] [Related]
19. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. Kumar S; Sarkar A; Sundar D Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781 [TBL] [Abstract][Full Text] [Related]
20. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease. Hong L; Simon JD J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]